Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0006632003
Wed, 04.05.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, May 4, 2022
MorphoSys AG Reports First Quarter 2022 Financial Results
- Monjuvi® U.S. net product sales of US$ 18.7 million (€ 16.6 million) for the first quarter 2022, a 21% year-over-year growth
- NCCN® updated the designation of Monjuvi to preferred regimen in its Clinical Practice Guidelines in Oncolog [ … ]
Thu, 28.04.2022
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, April 28, 2022
Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the first quarter 2022 on May 4, 2022 at 10:00 pm CEST (9:00 pm GMT; 4:00 pm EDT).
MorphoSys' Management team will host a conf [ … ]
Tue, 22.03.2022
MorphoSys AG
Media Release
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Minjuvi is a new therapeutic option for eligible DLBCL patients in Switzerland addressing an urgent unmet medical need
- In [ … ]
Wed, 16.03.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, March 16, 2022
MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
- Monjuvi(R) U.S. net product sales of US$ 23.6 million (€ 20.5 million) for the fourth quarter and US$ 79.1 million (€ 66.9 million) for the full year 2021
- Pipeline advances: enrollment [ … ]
Tue, 15.03.2022
MorphoSys AG
Media Release
National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
BOSTON, Mass., USA - March 15, 2022 - MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ: MOR), announced today that the [ … ]
Thu, 10.03.2022
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, March 10, 2022
Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the financial year 2021 on March 16, 2022 at 9:00 pm CET (8:00 pm GMT; 4:00 pm EDT).
MorphoSys' Management team will host a conference ca [ … ]
Thu, 10.03.2022
MorphoSys AG
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014
Planegg/Munich, Germany, March 10 2022
Ad hoc: MorphoSys AG reports non-cash impairment charge of approx. € 231 million on goodwill after consolidation of research and discovery functions; corresponding increase of Group operating expenses in 20 [ … ]
Mon, 24.01.2022
MorphoSys AG
MorphoSys ranked Number One in Germany for Female Representation at Leadership Level in European Women on Boards' Gender Equality Index Report
MorphoSys AG (FSE: MOR; NASDAQ: MOR) was acknowledged as a Best Practice Leader in the European Women on Boards' Gender Equality Index Report, ranking number one in Germany and number two among European hea [ … ]
Mon, 10.01.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, January 10, 2022
MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference
MorphoSys AG (FSE: MOR; NASDAQ: MOR), announced today that Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday January 12, 2022 at [ … ]
Fri, 07.01.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, January 07, 2022
MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
- Preliminary 2021 Monjuvi U.S. net product sales of US$ 79.1 million (€ 66.9 million)
- Anticipated 2022 Monjuvi U.S. net product sales in the range of US$ 110 to 135 million
MorphoSys AG (FSE: MOR; [ … ]